The nuts and bolts of omics for the clinical allergist

Virkud, Yamini; Kelly, Rachel S.; Wood, Caleb; Lasky‐Su, Jessica

doi:10.1016/j.anai.2019.09.017

Cited by 17 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the advent of data-driven "-omic" technologies, more potential biomarkers have been identified. 264 Here, we briefly review the more promising candidates that are being evaluated for immune monitoring with an expanded number in Figure 8. 265 subclasses after SLIT for temperate grass pollen.…”

Section: B I Omark Er S In Immune Monitoring Of Allerg En -S Pecifimentioning

confidence: 99%

“…Biomarkers that can identify responders, monitor treatment, predict durability of desensitization and determine adverse event risk would aid clinical decisions and delivery of targeted and effective treatment. With the advent of data‐driven “‐omic” technologies, more potential biomarkers have been identified 264 . Here, we briefly review the more promising candidates that are being evaluated for immune monitoring with an expanded number in Figure 8 265 …”

Section: Biomarkers In Immune Monitoring Of Allergen‐specific Immunotmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Breiteneder

Peng

Agache

et al. 2020

Allergy

159

150

View full text Add to dashboard Cite

show abstract

Section: B I Omark Er S In Immune Monitoring Of Allerg En -S Pecifimentioning

confidence: 99%

Section: Biomarkers In Immune Monitoring Of Allergen‐specific Immunotmentioning

confidence: 99%

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Breiteneder

Peng

Agache

et al. 2020

Allergy

159

150

View full text Add to dashboard Cite

show abstract

“…There are numerous limitations of multiomics that need to be considered before routine clinical applications, including the high cost, lack of unique protocols, and challenges in choosing the right sample (e.g., stool microbiota may not be representative of all gut microbes, especially the mucosa-adherent microbiota) [ 17 , 108 ]. A large sample size is needed for validation cohorts to overcome false-positive test results [ 17 , 109 , 110 ].…”

Section: Discussionmentioning

confidence: 99%

“…Untargeted metabolomics is limited by the inability to annotate all the molecules modified by microbial or host metabolism, and also possess the challenge of distinguishing the origin of molecules (host vs. microbial origin) [ 15 , 17 ]. The massive amount of data generated by these sophisticated methods also need advanced analytical computing [ 17 , 109 , 110 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis

et al. 2021

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common lethal, multisystemic genetic disorder in Caucasians. Mutations in the gene encoding the cystic fibrosis transmembrane regulator (CFTR) protein are responsible for impairment of epithelial anionic transport, leading to impaired fluid regulation and pH imbalance across multiple organs. Gastrointestinal (GI) manifestations in CF may begin in utero and continue throughout the life, resulting in a chronic state of an altered intestinal milieu. Inherent dysfunction of CFTR leads to dysbiosis of the gut. This state of dysbiosis is further perpetuated by acquired factors such as use of antibiotics for recurrent pulmonary exacerbations. Since the gastrointestinal microbiome and their metabolites play a vital role in nutrition, metabolic, inflammatory, and immune functions, the gut dysbiosis will in turn impact various manifestations of CF—both GI and extra-GI. This review focuses on the consequences of gut dysbiosis and its metabolic implications on CF disease and possible ways to restore homeostasis.

show abstract

“…With the advent of data-driven "-omic" technologies, more potential biomarkers have been identified. 227 Here, we briefly review the more promising candidates that are being evaluated for immune monitoring with an expanded number in Figure 8. 228…”

Section: Immunologically-mediated Non-specific Reactionsmentioning

confidence: 99%

Biomarkers in the Diagnosis and Therapy of Allergic Diseases and Asthma

Breiteneder¹,

Peng²,

Agache³

et al. 2020

Preprint

View full text Add to dashboard Cite

Modern healthcare requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of the distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions on the efficacy of the current management of allergic diseases requires further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen-immunotherapy with a special emphasis on specific IgE, microbiome and epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.

show abstract

The nuts and bolts of omics for the clinical allergist

Cited by 17 publications

References 58 publications

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis

Biomarkers in the Diagnosis and Therapy of Allergic Diseases and Asthma

Contact Info

Product

Resources

About